Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SEIZALAM vs VALTOCO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.
GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.
Status epilepticus,Acute repetitive seizures,Seizure clusters
Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy aged 2 years and older
0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day
5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.
Terminal elimination half-life is 15–20 hours in adults; prolonged in elderly and hepatic impairment (up to 40 hours).
Terminal elimination half-life: 15-17 hours (range 11-20 h) in adults; no dose adjustment for age or renal impairment is recommended, but clinical monitoring is prudent in hepatic impairment.
Hepatic via CYP3A4 and glucuronidation; active metabolite N-desmethylclobazam.
Hepatic via CYP3A4 and CYP2C9; active metabolite desmethyldiazepam (nordazepam)
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are excreted renally (approx. 70%) and fecal/biliary (approx. 30%).
Renal (70% as unchanged drug and metabolites, primarily glucuronide conjugate, with <2% as unchanged drug); biliary/fecal (30%)
Approximately 98% bound to albumin.
96% bound, primarily to albumin
1.0–1.5 L/kg; reflects extensive tissue distribution.
0.5-0.8 L/kg; approximates total body water, indicating extensive tissue distribution.
Oral: 70–90%; Intramuscular: 80–95% (relative to IV).
Intranasal: 75% (range 65-85%) relative to intravenous; rectal: 70-90% relative to intravenous.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: reduce dose by 50%; hemodialysis: 0.25 mg daily
No dosage adjustment required for mild to moderate renal impairment. Severe renal impairment (e GFR <15 m L/min): consider using lower doses due to increased exposure; use with caution.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Child-Pugh A or B: no adjustment needed. Child-Pugh C: reduce dose by 50% due to increased diazepam exposure.
0.01 mg/kg/dose (up to 0.5 mg) twice daily, titrate weekly to max 0.1 mg/kg/day (not to exceed adult max)
Age 6-17 years: 0.2 mg/kg intranasally, maximum single dose 20 mg. Administer as single dose per seizure cluster. Not recommended for children <6 years.
0.25 mg once daily initially; titrate slowly to 0.5 mg twice daily; max 2 mg/day
Elderly patients may have increased sensitivity; consider starting at lower end of dosing range (5-10 mg) and titrate based on response and tolerability. Use with caution due to risk of sedation and falls.
Risk of respiratory depression, hypotension, and cardiac arrest; coadministration with CNS depressants increases risk.
WARNING: RISK OF RESPIRATORY DEPRESSION AND CARDIAC ARREST WITH CONCOMITANT USE OF ALCOHOL OR OTHER CNS DEPRESSANTS; RISK OF SUBSTANCE ABUSE, DEPENDENCE, AND WITHDRAWAL; WITHDRAWAL SEIZURES; AND RISK OF SERIOUS SKIN REACTIONS.
Respiratory depression, hypotension, sedation, tolerance, withdrawal seizures, abuse potential, paradoxical reactions.
Risk of CNS depression and impaired motor function,Risk of abuse and dependence,Risk of withdrawal seizures upon abrupt discontinuation,Risk of serious skin reactions (e.g., Stevens-Johnson syndrome),Concomitant use with opioids may cause profound sedation, respiratory depression, coma, and death,Use in patients with compromised respiratory function or hepatic impairment requires caution
Hypersensitivity to benzodiazepines, severe respiratory insufficiency, myasthenia gravis, narrow-angle glaucoma.
Hypersensitivity to diazepam or any component of the formulation,Acute narrow-angle glaucoma,Concomitant use with opioid analgesics for acute treatment of seizure clusters (unless alternative treatments are not available)
Grapefruit and grapefruit juice may increase midazolam levels; avoid concurrent use. High-fat meals may reduce absorption of oral formulation; administer on empty stomach if possible.
No specific food interactions. Avoid alcohol consumption during VALTOCO use as it may increase CNS depressant effects.
First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restriction, preterm birth, neurodevelopmental deficits. Chronic use: Neonatal withdrawal syndrome, floppy infant syndrome.
Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used chronically. Second and third trimesters: May cause fetal benzodiazepine exposure leading to floppy infant syndrome, neonatal withdrawal, and central nervous system depression. Late third trimester or delivery: Risk of neonatal respiratory depression, hypotonia, and feeding difficulties.
M/P ratio 0.8; excreted into breast milk; levels low (0.1-0.5 mg/L). Monitor infant for sedation, poor feeding, weight loss. Caution recommended; alternative therapy if infant shows adverse effects.
Diazepam is excreted into breast milk with an M/P ratio approximately 0.3. The relative infant dose is low (2-5% of weight-adjusted maternal dose). Caution is advised due to potential accumulation in neonates (long half-life) causing sedation, poor feeding, and respiratory depression. Use only if clearly needed with infant monitoring.
Increased clearance and volume of distribution in pregnancy; dose increase of 30-50% often required to maintain therapeutic levels. Monitor trough concentrations and adjust as needed, especially in third trimester.
No specific dose adjustment recommended for VALTOCO during pregnancy for acute seizure management. However, due to increased volume of distribution and altered protein binding in pregnancy, a higher dose or more frequent dosing may be required for chronic use; clinical response should guide titration. Monitor for excessive sedation or respiratory depression as clearance may be reduced in late pregnancy.
SEIZALAM (midazolam) is a short-acting benzodiazepine used for acute seizure control. Administer IV/IM; intranasal formulation available. Onset within 2-5 minutes. Monitor respiratory depression, especially with concurrent opioids. Flumazenil is reversal agent. Avoid in narrow-angle glaucoma. Dose adjust in elderly and hepatic impairment.
VALTOCO (diazepam nasal spray) is indicated for acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) in patients with epilepsy aged 6 years and older. Administer one spray into one nostril; if needed, a second spray into the opposite nostril can be given after 4 hours if seizure activity persists. Do not use more than two doses per episode. Onset of action is rapid (within 2-5 minutes). Monitor for respiratory depression, especially in patients with compromised respiratory function or concomitant CNS depressants. Each spray delivers 5 mg or 10 mg diazepam; the dose depends on patient weight (5 mg for <40 kg, 10 mg for ≥40 kg). Tilt patient's head back slightly during administration. Do not reuse the device; discard after use.
Take exactly as prescribed; do not stop abruptly to avoid withdrawal seizures.,May cause drowsiness, dizziness; avoid driving or operating machinery.,Avoid alcohol and other CNS depressants.,Report any difficulty breathing, severe sedation, or rash immediately.,Store at room temperature away from light and moisture.
Use VALTOCO exactly as prescribed; only for seizure clusters, not for daily seizures.,Administer one spray into one nostril; do not prime the device.,After administration, tilt head back slightly and breathe normally.,If seizure activity continues after 4 hours, a second dose may be given in the opposite nostril.,Do not use more than two doses per seizure episode; if ineffective, seek emergency medical help.,Store at room temperature (20-25°C); protect from light and moisture.,Keep out of reach of children; discard device after use.,May cause dizziness, drowsiness, or coordination problems; avoid driving or operating machinery until effects wear off.,Inform healthcare provider of all medications, especially CNS depressants (e.g., alcohol, opioids, sedatives).,Do not consume alcohol while using VALTOCO.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SEIZALAM vs VALTOCO, answered by our medical review team.
SEIZALAM is a Benzodiazepine Anticonvulsant that works by Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion conductance and neuronal hyperpolarization.. VALTOCO is a Benzodiazepine Anticonvulsant that works by GABA-A receptor positive allosteric modulator; increases chloride ion conductance, hyperpolarizes neurons, and suppresses seizure activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SEIZALAM and VALTOCO depend on the specific clinical indication. These are both Benzodiazepine Anticonvulsant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SEIZALAM is: 0.5 mg orally twice daily, titrated weekly by 0.5 mg/day to a maximum of 4 mg/day. The standard adult dose of VALTOCO is: 5 mg, 10 mg, 15 mg, or 20 mg intranasally as a single dose based on weight; for patients weighing <50 kg: 5 mg, 10 mg for 50-75 kg, 15 mg for 75-100 kg, 20 mg for >100 kg. In adults, maximum dose is 20 mg per seizure cluster.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SEIZALAM and VALTOCO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SEIZALAM is classified as Category C. First trimester: Increased risk of major congenital malformations, particularly neural tube defects and orofacial clefts (OR 2.0-3.0). Second/third trimester: Fetal growth restrict. VALTOCO is classified as Category C. Diazepam (active moiety in VALTOCO) is Pregnancy Category D. First trimester: Associated with increased risk of congenital malformations, particularly cleft lip/palate, when used c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.